Adcom's focus on chronic cough drug could shape future of th

The U.S. FDA’s Pulmonary-Allergy Drugs Advisory Committee has a lot to discuss Nov. 17, but only one voting question: Does the evidence demonstrate that Merck & Co. Inc.’s gefapixant provides a clinically meaningful benefit to adults with refractory or unexplained chronic cough?

Related Keywords

, Merck Co , Allergy Drugs Advisory Committee , Chronic Cough , Radcom , Gefapixant , Merck Amp Co Inc , Advisory Committee , Shionogi Inc , Sivopixant , Bellus Health Inc , Camlipixant ,